IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9560 USD | -1.44% |
|
+6.22% | +3.91% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration